Skip to main content

Table 1 Prevalence of SpA in Latin American countries

From: Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis

Country

Study

Setting/Population

N

Diagnosis

Diagnostic criteria

n

Prevalence (%)

95% CI

Colombia

Londoño et al., 2018 [6]

6 Colombian cities

6693

uSpA

ESSG

n/r

0.28

0.13–0.61

AS

n/r

n/r

0.11

0.03–0.36

Fernández-Ávila et al., 2018 (CA) [7]

Colombia

n/r

AS

n/r

84,356

0.18

n/r

PsA

n/r

1670

0.004

n/r

Cuba

Reyes-Llerena et al., 2009 [8]

Havana

3155

AS

n/r

6

0.1

0.07–0.4

Male

1238

AS

n/r

4

0.3

n/r

Female

1917

AS

n/r

2

0.1

n/r

Mexico

Peláez-Ballestas et al., 2011 [9]

5 Mexican regions

19,213

AS

mNYC

n/r

0.1

0.1–0.2

Mexico City

4059

AS

mNYC

n/r

0.09

0.02–0.2

Nuevo León

4712

AS

mNYC

n/r

0.04

0.05–0.10

Yucatán

3195

AS

mNYC

n/r

0.04

0.05–0.10

Sinaloa

4879

AS

mNYC

n/r

0.2

0.1–0.40

Chihuahua

1647

AS

mNYC

n/r

0.6

0.2–1.1

Adjusted point prevalence, total

19,213

AS

mNYC

n/r

0.15

0.09–0.20

Male

7611

AS

mNYC

n/r

0.18

0.09–0.28

Female

11,602

AS

mNYC

n/r

0.11

0.05–0.17

Rodriguez-Amado et al., 2011 [10]

Nuevo León

4713

PsA

n/r

4

0.08

0.02–0.2

AS

mNYC

2

0.04

0.05–0.1

Alvarez-Nemegyei et al., 2011 [11]

Yucatán

3195

AS

mNYC

1

0.02

PsA

Surveying physician

1

0.02

Peláez-Ballestas et al., 2013 [12]

Mexico City

4059

SpA

ESSG

28

0.6

0.4–0.9

AS

mNYC

4

0.09

0.02–0.2

Del Río Nájera et al., 2016 [13]

Raramuri community

380

AS

mNYC

3

0.8

0.0–1.8

Julián-Santiago et al., 2016 [14]

Mixtec & Chontal communities

1061

AS

mNYC

1

0.09

0.002–0.5

Mixtec

937

AS

mNYC

1

0.1

0.002–0.5

Chontal

124

AS

mNYC

Peláez-Ballestas et al., 2009 (CA) [15]

Mexico City

9269

SpA

ESSG

36

0.9

0.6–1.3

axSpA

ASAS–1

39

0.9

0.7–1.3

axSpA

ASAS–2

10

0.2

0.1–0.4

Venezuela

Granados et al., 2016 [16]

Warao, Kari’ña, and Chaima communities

1537

SpA

mNYC

7

0.4

0.1–0.9

Warao

583

SpA

mNYC

Kari’ña

262

SpA

mNYC

2

0.7

0.09–2.7

Chaima

692

SpA

mNYC

5

0.7

0.2–1.6

  1. References are articles unless indicated as conference abstracts (CA)
  2. AS ankylosing spondylitis, ASAS Assessment in Spondyloarthritis International Society, CA conference abstract, CI confidence interval, ESSG European Spondyloarthropathy Study Group, mNYC modified New York criteria, N number of patients in study, n number of patients with specified condition, n/r not reported, SpA spondyloarthritis, uSpA undifferentiated spondyloarthritis